Anthracycline-induced cardiotoxicity

dc.contributorUniversidade Estadual Paulista (UNESP)
dc.creatorFerreira, Ana Lúcia dos Anjos
dc.creatorMatsubara, Luiz Shiguero
dc.creatorMatsubara, Beatriz Bojikian
dc.date2014-05-27T11:23:41Z
dc.date2016-10-25T18:26:03Z
dc.date2014-05-27T11:23:41Z
dc.date2016-10-25T18:26:03Z
dc.date2008-10-01
dc.date.accessioned2017-04-06T01:32:36Z
dc.date.available2017-04-06T01:32:36Z
dc.identifierCardiovascular and Hematological Agents in Medicinal Chemistry, v. 6, n. 4, p. 278-281, 2008.
dc.identifier1871-5257
dc.identifierhttp://hdl.handle.net/11449/70604
dc.identifierhttp://acervodigital.unesp.br/handle/11449/70604
dc.identifier10.2174/187152508785909474
dc.identifier2-s2.0-54949128285
dc.identifierhttp://dx.doi.org/10.2174/187152508785909474
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/891680
dc.descriptionThe anthracyclines constitute a group of drugs widely used for the treatment of a variety of human tumors. However, the development of irreversible cardiotoxicity has limited their use. Anthracycline-induced cardiotoxicity can persist for years with no clinical symptoms. However, its prognosis becomes poor after the development of overt heart failure, possibly even worse than ischemic or idiopathic dilated cardiomyopathies. Due to the successful action of anthracyclines as chemotherapic agents, several strategies have been tried to prevent/ attenuate their side effects. Although anthracycline-induced injury appears to be multifactorial, a common denominator among most of the proposed mechanisms is cellular damage mediated by reactive oxygen species. However, it remains controversial as to whether antioxidants can prevent such side effects given that different mechanisms may be involved in acute versus chronic toxicity. The present review applies a multisided approach to the critical evaluation of various hypotheses proposed over the last decade on the role of oxidative stress in cardiotoxicity induced by doxorubicin, the most used anthracycline agent. The clinical diagnosis and treatment is also discussed. © 2008 Bentham Science Publishers Ltd.
dc.languageeng
dc.relationCardiovascular and Hematological Agents in Medicinal Chemistry
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCardiomyopathy
dc.subjectDNA damage
dc.subjectDoxorubicin
dc.subjectFree radicals
dc.subjectOxidative stress
dc.subjectReactive Oxygen Species
dc.subjectalpha tocopherol
dc.subjectamifostine
dc.subjectanthracycline derivative
dc.subjectantioxidant
dc.subjectascorbic acid
dc.subjectbeta adrenergic receptor blocking agent
dc.subjectbeta carotene
dc.subjectcannabinoid 1 receptor
dc.subjectcannabinoid 1 receptor antagonist
dc.subjectcyclophosphamide
dc.subjectcytarabine
dc.subjectdigoxin
dc.subjectdipeptidyl carboxypeptidase inhibitor
dc.subjectDNA topoisomerase (ATP hydrolysing)
dc.subjectdoxorubicin
dc.subjectflavonoid
dc.subjectglutathione
dc.subjectidarubicin
dc.subjectinducible nitric oxide synthase
dc.subjectlycopene
dc.subjectolive oil
dc.subjectpolyphenol derivative
dc.subjectprobucol
dc.subjectrazoxane
dc.subjectreactive nitrogen species
dc.subjectreactive oxygen metabolite
dc.subjectretinol
dc.subjectselenium
dc.subjectubiquinone
dc.subjectunindexed drug
dc.subjectantioxidant activity
dc.subjectaspartate aminotransferase blood level
dc.subjectcardiomyopathy
dc.subjectcardiotoxicity
dc.subjectcardiovascular risk
dc.subjectclinical feature
dc.subjectcreatine kinase blood level
dc.subjectdiagnostic value
dc.subjectdose response
dc.subjectdrug dose reduction
dc.subjectdrug efficacy
dc.subjectdrug induced disease
dc.subjectdrug safety
dc.subjectdrug withdrawal
dc.subjectearly diagnosis
dc.subjectECG abnormality
dc.subjectechocardiography
dc.subjectelectrocardiography
dc.subjectfollow up
dc.subjecthealth care cost
dc.subjectheart arrhythmia
dc.subjectheart failure
dc.subjectheart muscle biopsy
dc.subjectheart protection
dc.subjectheart transplantation
dc.subjecthuman
dc.subjecthypotension
dc.subjectincidence
dc.subjectlactate dehydrogenase blood level
dc.subjectneoplasm
dc.subjectnonhuman
dc.subjectoxidative stress
dc.subjectpathogenesis
dc.subjectprimary prevention
dc.subjectprognosis
dc.subjectprotein expression
dc.subjectQRS complex
dc.subjectQT prolongation
dc.subjectreview
dc.subjectrisk factor
dc.subjectside effect
dc.subjectsingle drug dose
dc.subjectST segment
dc.subjecttachycardia
dc.subjectAnimals
dc.subjectAntibiotics, Antineoplastic
dc.subjectCalcium
dc.subjectDNA Damage
dc.subjectElectrocardiography
dc.subjectHeart
dc.subjectHumans
dc.subjectOxidative Stress
dc.titleAnthracycline-induced cardiotoxicity
dc.typeOtro


Este ítem pertenece a la siguiente institución